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Abstract 
Androgen deficiency is associated with an increased incidence of  cardiovascular disease. There is evidence that 
thromboembolic disease as well as myocardial infarction in hypogonadic males are mediated by low baseline 
fibrinolytic activity. Hypogonadism in males is associated with an enhancement of fibrinolytic inhibition via increased 
synthesis of the plasminogen activator inhibitor PAl 1. On the other hand, stanozoiol and danazol reduce PAl 1 and 
are associated with increased fibrinolytic activity. However, in male abusers of anabolic steroids the net effect on the 
haemostatic system may change from anti- to prothrombotic; there appears to be an individual threshold dose above 
which thrombogenic effects on platelets and vasomotion may overcome the profibrinolytic effects on PAl 1. There are 
numerous reports on weight-lifters dying of atherothrombotic ischemic heart disease while abusing anabolic steroids. 
Androgens are known to have profound effects on carbohydrate and lipid metabolism. In fact, much of the individual 
inconsistency of the effects of androgens on fibrinolytic and haemostatic activity appears to be based on the close 
interrelationship of these metabolic systems. Androgens may have urifavourable effects on the HDL/LDL cholesterol 
ratio, on triglyceride levels and on the insulin/insulin-like growth factor 1 ( IGF 1) system. Hypertriglyceridemia as 
well as insulin resistance are both associated with low fibrinolytic activity and increased PAl 1 levels. On the other 
hand, lipoprotein(a), a recently acknowledged independent risk factor of CVD was shown to respond favourable to 
androgen treatment, in men as well as in women. In women, agonistic as well as antagonistic effects of estrogens and 
progestins need to be taken into account. In fact, estradiol may modulate testosterone effects on haemostasis. 
Androgen medication in premenopausal women, such as danazol, was found to reduce PAI 1 suggesting an 
improvement of the fibrinolytic activity. Also, in hormone replacement therapy (HRT) androgenic progestins or 
complex compounds with androgenic effects are associated with a marked reduction of PAI 1 and an improvement 
of fibrinolytic activity. Further improvement of fibrinolytic activity may be associated with the marked decrease of 
lipoprotein (a) (Lp(a)) in women on androgenic HRT. However, little is known on the interrelationship of estrogens, 
19-nortestosterone or progesterone derivatives and testosterone, an interrelationship that may have substantial impact 
on the metabolic and particularly haemostatic net effects of a preparation. In summary, information on the effects of  
androgens on haemostasis is limited and may be particularly incomplete due to the fact that interaction with other 
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sex steroids appears to be an important confounder. In any case, there are numerous effects of synthetic androgens 
on the synthesis and release of haemostatic factors, namely an increase of the inhibitors of coagulation and a decrease 
of the inhibitor of the fibrinolytic system. However, the use of androgens in patients with congenital deficiencies of 
these coagulation factors or previous events of cardiovascular disease has yielded disappointing results. On the other 
hand, particularly the reduction of fibrinolytic inhibition (PAI 1) and Lp(a) were considered favourable effects of 
androgens with regard to the risk of cardiovascular disease. Differences between preparations with pronounced 
androgenic versus antiandrogenic effects and the effect of combined preparations need to be studied in much more 
detail. The profibrinolytic effects of androgens may be of particular interest with regard to favourable effects of HRT 
on cardiovascular disease. 
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1. Haemostatic effects of androgens in men 
The gender ratio of mortality from cardiovascu- 
lar disease (CVD) before the age of 50 years was 
shown to be > 2. Beside the well acknowledged 
beneficial effects of estrogens, hazardous effects of 
the androgens may also play a role [1]. In animal 
models and experimental studies androgens were 
shown to have significant effects on the extracellu- 
lar matrix, namely the collagen/elastin ratio [2], 
extracellular NO-production [3] and the arach- 
nidonic metabolism in platelets and endothelial 
cells [4]. These mechanisms may have marked 
indirect effects on haemostatic function: an in- 
crease of blood pressure [2], vascular tone [3], and 
platelet aggregability [5] would translate into 
rather unfavourable prothrombotic effects on the 
cardiovascular risk profile. In fact, all these mech- 
anisms could potentially antagonize the effects of 
estrogens that have recently been suggested to be 
responsible for the reduction of CVD in post- 
menopausal women on estrogen replacement ther- 
apy (ERT). 
On the other hand, there is evidence of a positive 
correlation of androgen levels and fibrinolytic ac- 
tivity. Fibrinolytic activity is physiologically deter- 
mined by the activity of free tissue-plasminogen 
activator (t-PA), a serine protease that converts 
plasminogen to the active fibrinolytic protease 
plasmin. Regulation of fibrinolytic activity mainly 
depends on the release of t-PA from the endothelial 
cell into the circulation and the amount of the t-PA 
inhibitor (PAl 1) present in the circulation [6]. The 
latter may be released from endothelial or syn- 
thethized by hepatic cells. High levels of PAl 1 
have been shown to significantly reduce fibrinolytic 
reactivity (as measured by means of stimulation 
tests), to be associated with an increased risk of 
post-surgical thrombosis [7] and a poor prognosis 
after myocardial infarction [8,9]. The androgen-as- 
sociated reduction of PAI 1 is therefore likely to be 
favourable with respect to CVD: fibrinolytic activ- 
ity and reactivity is increased and a potential risk 
factor of  venous or arterial thrombotic disease is 
reduced. However, it should be noted that this 
mechanism only operates as long as t-PA release is 
not altered. If  t-PA would be reduced as well, a 
reduction of  PAI 1 levels would have no net effect 
on the fibrinolytic activity. 
Obviously, the effect of androgens on the 
haemostatic system is rather complex and factors 
such as dose of  the androgen, agonistic or antago- 
nistic effects of  additional steroids and state of the 
haemostatic system prior to treatment are of cru- 
cial importance for the net clinical effect [10]. In 
males, clinical and experimental work in hypogo- 
nadic men, patients with inhibitor deficiencies or 
predisposition to CVD, as well as weight-lifters 
abusing anabolic steroids, have largely improved 
our understanding of androgenic effects due to the 
negligible role of other sex steroids. 
I. 1. Hypogonadism 
Atherosclerosis is associated with low rather 
than high testosterone levels [11] in males. More- 
over, male survivors of myocardial infarction have 
elevated rather than low levels of estrogens [12]. 
These data suggest that male hypogonadism 
may be associated with metabolic changes predis- 
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posing to atherogenesis and ischaemic heart dis- 
ease. There is evidence that at least one factor is 
the reduced fibrinolytic activity in hypogonadic 
males [13]. It was demonstrated recently that the 
underlying mechanism is the inverse relationship 
of testosterone and PAI 1 in this range of testos- 
terone concentration [14]. Thus, with low testos- 
terone levels high PAl 1 concentrations will 
constitute a rather high threshold of fibrinolytic 
activation. The release of very high quantities of 
t-PA is required to overcome immediate inactiva- 
tion by PAl 1 and eventually result in actual 
plasmin generation. PAl 1 overexpression has 
long been recognized as a risk marker associated 
with a high incidence of thromboembolic disease 
after hip surgery [7] and a poor prognosis in 
young survivors of myocardial infarction [8,9] and 
intravascular, mainly prothrombotic as well as 
extravascular atherogenetic pathomechanisms 
have been discussed [15]. In fact, hypogonadic 
men appear to suffer from a high incidence of 
thromboembolic disease [13]. 
1.2. Tes tos terone  
Supraphysiological doses of testosterone have 
been investigated as a hormonal male contracep- 
tive treatment. In a recent paper Anderson and 
coworkers report on changes from pretreatment 
baseline of several hemostatic variables during 
and after up to 52 weeks of treatment with 200 
mg testosterone oenanthate weekly i.m. [16]. 
Fibrinogen levels decreased by about 15% within 
16 weeks of treatment, suggesting a favourable 
effect on blood viscosity. However, there was a 
slight increase of haemoglobin concentration and 
hematocrit as well as white blood cell count. Also, 
a slight increase of antithrombin III, and a de- 
crease of protein C and S activity was noted. The 
prothrombin fragment F 1 + 2 was slightly in- 
creased. The authors summarized that these 
changes indicate an increase of coagulatory activ- 
ity which may theoretically increase the risk of 
thrombosis in predisposed patients. On the other 
hand, a decrease of PAl 1 activity was observed 
predominantly during the first months of treat- 
ment. While this finding was discussed as evidence 
of improved fibrinolytic activity and reduced arte- 
rial risks, it was concluded that the overall effect 
of supraphysiological doses of testosterone have 
no marked prothrombotic effect. 
1.3. S tanozo lo l  
Anabolic steroids have long been known to 
enhance synthesis of some plasmatic proteins such 
as fibrinogen and plasminogen [17]. Much interest 
focused on the effects on protein C and an- 
tithrombin III, inhibitors of the coagulatory en- 
zyme thrombin. Congenital deficiencies of these 
inhibitors are known predispositions to throm- 
boembolic disease and the capacity of stanozol 
and other anabolic steroids to increase plasma 
levels even in deficient subjects raised some expec- 
tations on potential therapeutic effects of andro- 
gens on the risk of thromboembolic complications 
in antithrombin III deficiency [18], protein C defi- 
ciency [19], postoperative thrombosis [20] and 
even in Raynaud's syndrome [21]. Unfortunately, 
even though stanozolol proved to increase plasma 
levels of antithrombin III and protein C in male 
and female patients suffering from a congenital 
deficiency syndrome, the clinical effects were 
rather disappointing [18]. A likely explanation is 
that stanozolol failed to improve the insufficient 
anticoagulant function. Indirect evidence for this 
hypothesis has been provided by studies on the 
effect of synthetic androgens on reaction products 
of. coagulatory activity. Two recent reports con- 
firmed an increase of plasma concentration and 
activity of inhibitors under therapy but failed to 
find a reduction of coagulatory activity as de- 
picted by fibrinopeptide A (FPA) plasma levels 
[21,221. 
On the other hand, the enhancement of 
fibrinolytic activity [24] by synthetic androgens 
was confirmed by studies in patients with defec- 
tive fibrinolysis [25,26]. Stanozolol was shown to 
decrease the plasma levels and activity of PAI 1 
thus increasing the fibrinolytic activity by reduc- 
tion of the inhibitory threshold [27]. However, the 
clinical use of androgens for prevention of throm- 
boembolic disease was limited by early reports on 
thrombotic complications of high dose stanozolol 
[28]. These clinical data suggested a dose depen- 
dency of the net effects of androgens: low doses of 
150 U.H. Winkler / Maturitas 24 (1996) 147-155 
stanozolol may improve the fibrinolytic activity 
but high doses may have predominantly procoag- 
ulatory effects [10]. Further evidence for this con- 
cept was derived from studies in male abusers of 
anabolic steroids. 
antithrombotic effects on the fibrinolytic capacity. 
So, the dose dependency of the male response to 
androgens provides further evidence for the clini- 
cal significance of the individual predisposition. 
1.4. Anabolic steroids 2. Haemostatic effects of androgens in women 
In general, young male athletes, namely weight- 
lifters, carry very few risk factors for CVD. It is 
conceivable that athletes themselves tend to be- 
lieve that in spite of adverse effects on lipids [29] 
and carbohydrates [30] the abuse of anabolic 
steroids would not be harmful. However, after a 
first report on a case of myocardial infarction in a 
22-year-old weight-lifter using anabolic steroids 
[31], several other cases of ischaemic heart disease, 
stroke and arterial thromboembolism were pub- 
lished [10]. The absence of classical risk factors, 
the youth of the patients and the lack of 
atherosclerotic lesions suggested a atherthrom- 
botic rather than atherogenic pathomechanism 
raising questions on the prothrombotic effects of 
high dose androgens [32]. 
It has recently been suggested that an increased 
platelet aggregability in vivo might mediate this 
prothrombotic effect of high dose androgens: 
platelet aggregability with adenosin diphosphate 
and collagen was significantly increased in abusers 
of anabolic steroids when compared to their fel- 
low male weight-lifters who did not use androgens 
[33]. Platelet aggregability is largely dependent on 
the arachnidonic acid metabolism and an effect of 
high dose androgens on both platelet [5], as well 
as vascular cyclooxygenase activity [34] has been 
demonstrated. Thus, high dose anabolic steroids 
are capable of increasing vascular tone and reac- 
tivity, i.e. blood pressure, and platelet aggregabil- 
ity (i.e. blood coagulability). Obviously, these 
effects are clearly prothrombotic and in opposi- 
tion to the antithrombotic effects via improved 
fibrinolytic action. 
In summary, the numerous cases of arterial 
thrombotic disease in abusers of androgens clearly 
indicate that at least in some individuals the net 
effect of high dose anabolic steroids on lipids, 
carbohydrates, platelets and vascular function 
may be prothrombotic, i.e. may overcome the 
Among the most impgrtant factors that may 
modulate the hemostatic as well as all metabolic 
effects of steroid hormones is gender and the 
hormonal milieu. In principle, the hormonal 
milieu may modulate the effects of a certain 
steroid by lowering the impact of the competing 
steroid on a particular target cell (i.e. the effects 
on bioavailability and receptor expression) or by 
competing on the metabolic level (i.e. at the 
protein-level either directly or via second messen- 
gers). Examples for the latter are the modulation 
of lipid profiles or vascular tone resp flow in 
estrogen versus estrogen/progestin-androgen com- 
binations [35]. So, the effects of androgens on the 
haemostatic system in women may be quite differ- 
ent from those in men. 
2.1. Hyperandrogenism 
The syndrome of policystic ovaries (PCO), a 
clinical diagnosis frequently associated with hy- 
perandrogenism in premenopausal women, is fre- 
quently associated with a complex dysfunction of 
the carbohydrate metabolism [36]. In fact, hyper- 
insulinemia and high levels of the insulin-like 
growth factor 1 (IGF 1) have been shown to 
sustain the dysregulation of ovarian function by 
interfering with the pulsatility of gonadotrophin 
release. In premenopausal women hyperandrogen- 
emia is frequently associated with an impaired 
glucose tolerance, a metabolic dysregulation that 
is known to have distinct effects on fibrinolytic 
function [37,38]. Evidence from in vitro and in 
vivo studies has suggested that hyperinsulinemea 
as well as high levels of IGF 1 increase synthesis 
and release of PAl 1. It has been concluded that 
much of the cardiovascular risk associated with 
insulin resistance [39] is mediated by this reduc- 
tion of fibrinolytic activity [40]. Unfortunately, 
studies of the hemostatic system in hyperandro- 
U.H. Winkler / Maturitas 24 (1996) 147-155 151 
genemic women are scarce. In a preliminary study 
on the hemostatic effects of oral contraceptives we 
investigated the fibrinolytic system in 29 pre- 
menopausal women prior to OC therapy. PAl 1 
was positively correlated with testosterone levels 
suggesting a different regulation of PAl 1 than in 
men. However, we did not study the carbohydrate 
metabolism in these women. So, increased PAl 1 
in our hyperandrogenic patients may be induced 
by impaired glucose tolerance rather than testos- 
terone levels. In any case, the interrelationship of 
these both mechanisms may result in a decrease of 
fibrinolytic activity in hyperandrogenic women. 
2.2. Danazol 
Danazol is a weak androgen. Beside its clinical 
use in endometriosis and mastalgia danazol has 
well acknowledged effects on the synthesis of 
certain haemostatic factors. There are favourable 
effects in deficiencies of the first component of the 
complement system C1, in protein C deficiency, 
antithrombin III deficiency and even in factor 
VIII deficiency [41]. However, with the exception 
of the C1 deficiency, apparently only laboratory 
findings were found to improve in long term 
danazol therapy of these deficiencies, while hemo- 
static function and clinical symptoms did not. 
In a study of 20 women on danazol we have 
focused on the effect on haemostatic function as 
well as risk markers of CVD. We failed to find 
any prothrombotic effect of this weak androgen. 
In fact, we demonstrated a significant reduction of 
PAl 1 concentration and activity and a decrease 
of all reaction products of thrombin activity and 
fibrin turnover [42]. So, these findings in pre- 
menopausal women without haemostatic disease 
were very much in line with what has been found 
in low dose stanozolol therapy in males: no in- 
crease in reaction products of thrombin genera- 
tion and activity associated with a decrease of the 
fibrinolytic threshold suggesting an improvement 
of the fibrinolytic capacity may be considered 
beneficial in the context of venous thromboem- 
bolism. Similar conclusions were drawn by a re- 
cent study of Ford and coworkers in 18 women 
on 600 mg danazol for treatment of endometriosis 
[23]. However, in this study, an increase of the red 
cell count, haemoglobin levels, the hemoatocrit 
and the platelet count (not platelet function) was 
observed. The authors concluded that a potential 
adverse rheological effect should be considered in 
the treatment of individuals at risk from arterial 
cardiovascular disease. 
2.3. Hormone replacement, testosterone implants 
and complex androgenic steroids 
Menopause is known to be a risk factor for 
cardiovascular disease. There is evidence of 
prothrombotic changes associated with the cessa- 
tion of ovarian function, mainly an increase of 
factor VII [43], fibrinogen [44] and of PAI 1 [45]. 
The beneficial effect of hormone replacement 
therapy (HRT) was suggested to be in part medi- 
ated by a reduction of these prothrombotic 
changes. Moreover, differential effects of the vari- 
ous steroids, namely the differential androgenic 
potency of each combination may yield different 
metabolic effects justifying a new evaluation of 
the various preparations with regard to the reduc- 
tion of cardiovascular risks. 
Such differential effects must be considered 
mainly when progestins are added. Sporrong and 
coworkers compared the effects of estradiol in 
combination with norethisterone acetate versus 
megestrol acetate. The 19-nortestosterone deriva- 
tive was associated with a reduction of F VII and 
AT III activity, while no such changes were seen 
in women on megestrol acetate [46]. The authors 
considered these changes to be minor and in 
accord with the concept of reduced CVD in HRT 
users. However, among their 60 patients, two 
cases of thromboembolic disease were observed 
during the observation period of 1 year. Both 
occurred in the group treated with the proges- 
terone derivative megestrol acetate. So even 
though there may be unfavourable effects of an- 
drogenic progestins on the lipid profile, the risk of 
thrombotic complications may be reduced in users 
of 19-nortestosterone derivatives containing HRT 
preparations. 
Fibrinolytic activity as well as t-PA and PAl 1 
have been studied in postmenopausal women 
treated with a complex steroid with androgenic as 
well as estrogenic and progestational properties 
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(tibolone). These effects were studied longitudinal 
[47] as well as in a controlled comparative study. 
The latter compared haemostatic effects of this 
compound with those of an estradiol-cyproterone 
acetate (CPA) combination [48]. While CPA in 
combination with estrogen had no effects on the 
fibrinolytic activity, the androgenic compound 
was associated with a decrease of PAl 1 suggest- 
ing an increased fibrinolytic activity. In this study 
an increased rate of plasmin generation was confi- 
rmed by measurements of the plasmin-antiplas- 
min complexes, which were increased in women 
on tibolone. It may be argued that the reduction 
of a well known risk marker of CVD and the 
enhancement of the fibrinolytic activity con- 
tributes to an improvement of the overall effect 
on CVD risk factors. 
There is evidence that PAl 1 is mainly regulated 
by the hepatocyte and may only to a very limited 
extend be affected by transdermal ERT. Oral 
conjugated equine estrogens (CEE) were shown to 
be associated with reduced PAI 1 in a short term 
crossover protocol, a transdermal estradiol deliv- 
ering system had no effect [49]. This finding was 
recently confirmed by a comparative study with a 
new transdermal estradiol delivering system [50]. 
The authors speculate that the lack of the hepatic 
first pass on the hepatic insulin-like growth factor 
1 (IGF 1) synthesis [51] might have prevented 
a comparable effect of the transdermal estra- 
diol. Stephenson and coworkers have recently 
confirmed that transdermal estradiol application 
in combination with progestins is associated with 
less impact on hepatic regulation of lipoproteins 
and carbohydrates than oral CEE [52]. However, 
androgens may modulate the hepatic response. It 
may be argued that a reduction of the estrogen 
induced triglyceride enhancement and an im- 
provement of the fibrinolytic activity with andro- 
genic steroids is a valuable contribution to the 
general antithrombotic effects of HRT [45] and 
may be particularly interesting in women predis- 
posed to thrombotic disease. 
Thorn and coworkers compared the effects of 
testosterone implants in combination with HRT 
with various regimen of HRT without testos- 
terone implants. Although the number of vari- 
ables studied was rather limited, the lack of 
differential effects on factor X activity suggested 
that the androgen did not induce surplus coagula- 
tory activity [53]. Unfortunately, nothing is 
known about the fibrinolytic response to testos- 
terone implants. Further research on these thera- 
peutic options is badly needed: a potential 
beneficial effect of testosterone implants on 
fibrinolytic capacity may have been overlooked 
and may turn out to be particularly favourable in 
women with certain risk profiles. 
Recently, the interrelationship of the 
fibrinolytic system with lipoprotein(a) (Lp(a)) has 
gained considerable interest. Lp(a) is an indepen- 
dent risk factor of CVD in male high risk popula- 
tions and possibly also in postmenopausal women 
[54]. There is a remarkable homology of Lp(a) 
with the proenzyme of the fibrinolytic system, 
plasminogen. Atherothrombotic effects of Lp(a) 
may be mediated by competitive binding at plas- 
minogen binding sites both on the endothelium 
and within the fibrin matrix of fresh clots [55]. 
Additionally, an Lp(a) induced up-regulation of 
the endothelial PAI 1 synthesis may increase the 
threshold of fibrinolytic inhibition [56]. The rela- 
tive contribution of each of these mechanisms is 
still not clear. In an animal model, increased 
Lp(a) serum levels were shown to be associated 
with inhibition of the fibrinolytic response and 
atherogenesis [57]. 
The finding of decreased Lp(a) concentration in 
HRT is therefore considered beneficial. Andro- 
gens such as stanozolol and danazol have been 
shown to reduce the serum concentration 
markedly [58]. While estrogen replacement alone, 
as well as in combination with progesterone 
derivatives, appears to reduce Lp(a) only by up to 
20% [59], tibolone was reported to reduce Lp(a) in 
longitudinal studies by 50% [60,61]. However, 
comparative trials on the differential effects of 
these preparations are still scarce. Moreover, sev- 
eral reports on hormonal effects on Lp(a) have 
noticed that these effects appear to depend on the 
pretreatment Lp(a) level, i.e. the effects were most 
pronounced in women with markedly elevated 
pretreatment values [58,60,61]. Thus, differential 
hormonal effects on Lp(a) may be biased and 
should be studied in a subgroup of women with 
elevated ()0.3 g/l) Lp(a) baseline values. 
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3. Summary 
Data on the haemostatic effects of androgens 
are scarce. There is evidence of a dose response 
with regard to the effects on blood pressure, 
platelet aggregability, haemoglobin, platelet and 
red cell count, and coagulatory activation which 
was found only in men on superphysiological 
doses of testosterone and abusers of anabolic 
steroids. High dose danazol therapy is still consid- 
ered in patients with C1 deficiency and autoim- 
mune hemolytic anemia, but not in AT III or 
protein C/S deficiency. A thrombotic risk, partic- 
ularly an arterial risk cannot be ruled out in these 
dose ranges, mainly in predisposed patients. How- 
ever, with lower doses a more antithrombotic 
profile emerged with an increase of coagulation 
inhibitors and a decrease of fibrinolysis inhibitors. 
Also, even at low doses a decrease of fibrinogen 
levels was found. It has been noted that these 
changes are in contrast with the effects of 
ethinylestradiol [16], suggesting that combination 
therapy may alleviate unfavourable effects of es- 
trogens. Unfortunately, there is only insufficient 
data on the effects of combination therapies. 
Studies addressing these issues need to take into 
account potential confounders such as the pre- 
treatment risk profile with regard to the hemo- 
static system as well as the lipid and carbohydrate 
metabolism. Pretreatment Lp(a) as well as insulin- 
like growth factor 1 levels may have substantial 
impact on the net effect of such combination 
therapies and may be of particular interest in 
postmenopausal women. 
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